Literature DB >> 8710820

[Bronchial asthma--a cost of illness analysis].

D Nowak1, T Volmer, R Wettengel.   

Abstract

We performed an economic evaluation of the costs of asthma in Germany. Estimates of direct medical expenditures and indirect costs were derived from official health statistics of 1992. Adding up direct and indirect costs, the total sum is approximately 2.66 billions ECU which is equivalent to 5.13 billions DM or 3.11 billions US-$, respectively, for a total population of 80.3 millions. Direct costs make up 61.5% of this sum and comprise of outpatient medical care, drugs, hospital treatment, rehabilitation and compensation for occupational asthma as well as sickness benefits. Indirect costs of 38.5% are caused by payments for days off work, premature retirement and premature death due to asthma. Based on these figures, we speculate that an optimised treatment according to published recommendations should be accompanied by a reduction of the high amount of indirect costs.

Entities:  

Mesh:

Year:  1996        PMID: 8710820

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  3 in total

1.  Cost effectiveness of fluticasone propionate and flunisolide in the treatment of corticosteroid-naive patients with moderate asthma.

Authors:  T Volmer; A Kielhorn; H H Weber; K J Wiessmann
Journal:  Pharmacoeconomics       Date:  1999-11       Impact factor: 4.981

2.  Cost effectiveness of fluticasone and budesonide in patients with moderate asthma.

Authors:  K O Steinmetz; T Volmer; M Trautmann; A Kielhorn
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

3.  Healthcare costs and resource utilization of asthma in Germany: a claims data analysis.

Authors:  Christian Jacob; Benno Bechtel; Susanne Engel; Peter Kardos; Roland Linder; Sebastian Braun; Wolfgang Greiner
Journal:  Eur J Health Econ       Date:  2015-02-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.